Publication Name	World Journal of Gastrointestinal Pathophysiology
Manuscript ID	21195
Country	Spain

Received	2015-06-30 15:49
Peer-Review Started	2015-07-05 14:42
To Make the First Decision	2015-07-27 15:56
Return for Revision	2015-07-31 12:26
Revised	2015-08-14 20:56
Second Decision	2015-10-14 08:47
Accepted by Journal Editor-in-Chief	2015-10-17 05:13
Accepted by Executive Editor-in-Chief	2015-10-27 18:38
Articles in Press	2015-10-27 18:38
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-03 19:46
Publish the Manuscript Online	2015-11-17 12:17

ISSN	2150-5330 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Faecal calprotectin: Management in inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	José Manuel Benítez and Valle García-Sánchez
Funding Agency and Grant Number
Corresponding Author	José Manuel Benítez, MD, Department of Gastroenterology, University Hospital Reina Sofia (Córdoba), Avda.Menéndez Pidal s/n, 14004 Córdoba, Spain. jmbeni83@hotmail.com
Key Words	Faecal calprotectin; Inflammatory bowel disease; Biomarkers; Ulcerative colitis; Crohn’s disease; Relapse
Core Tip	The surveillance of inflammatory bowel disease (IBD) course is needed to select the patients with worse prognosis and to adapt an early therapeutic strategy. Faecal calprotectin constitutes a surrogate marker of intestinal inflammation and a robust alternative to invasive procedures as endoscopy. This biomarker has been demonstrated reliable and accuracy in different aspects of IBD such as diagnosis of IBD, activity assessment, response to treatment and relapse pre-diction. Although a cut-off level of calprotectin has not been fully established, the combination with other biomarkers allows an appropriate management of the patient.
Publish Date	2015-11-17 12:17
Citation	Benítez JM, García-Sánchez V. Faecal calprotectin: Management in inflammatory bowel disease. World J Gastrointest Pathophysiol 2015; 6(4): 203-209
URL	http://www.wjgnet.com/2150-5330/full/v6/i4/203.htm
DOI	http://dx.doi.org/10.4291/wjgp.v6.i4.203

Full Article (PDF)	WJGP-6-203.pdf
Full Article (Word)	WJGP-6-203.doc
Manuscript File	21195-Review.docx
Answering Reviewers	21195-Answering reviewers.pdf
Audio Core Tip	21195-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	21195-Conflict-of-interest statement.pdf
Copyright License Agreement	21195-Copyright assignment.pdf
Peer-review Report	21195-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21195-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21195-Scientific misconduct check.pdf
Scientific Editor Work List	21195-Scientific editor work list.pdf